SLC5A2 and heart failure: The initial evidence of the efficacy of SGLT2 inhibitors in the clinical trial setting was noted in EMPA-REG-OUTCOME [19]—where it was determined that individuals hospitalized for heart failure, and who were randomized into treatment groups had a two-fold reduced risk of being re-hospitalized or dying in the first 1–3 months of the first heart failure event [19].